# DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

> **NCT06388122** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 100 (estimated)

## Conditions studied

- HER2-negative Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT06388122
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2031-06-15
- **Final completion:** 2031-06-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388122, "DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06388122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*